
Emcure Pharmaceuticals Ltd. Emcure Pharma
Emcure Pharma
Emcure Pharmaceuticals Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
| Ex-Date | Purpose |
|---|---|
07-11-2024 | Quarterly Results |
06-02-2025 | Quarterly Results |
22-05-2025 | Quarterly Results & Final Dividend & Audited Results |
11-11-2025 | Quarterly Results |
04-02-2026 | Quarterly Results |
05-05-2026 | Audited Results & Final Dividend |
06-08-2026 | Quarterly Results |
03-11-2026 | Quarterly Results |
News
Emcure Pharmaceuticals zooms on reporting 34% rise in Q2 consolidated net profit
The total consolidated income of the company has increased by 24.23% at Rs 2,823.73 crore for Q2FY27
Emcure Pharmaceuticals reports 34% rise in Q2 consolidated net profit
The total consolidated income of the company has increased by 24.23% at Rs 2,823.73 crore for Q2FY27
Emcure Pharma - Quaterly Results
Emcure Pharmaceuticals informs about investor presentation
Emcure Pharma reports Profit after tax of Rs 2484.28 Mln, in the September 2026 quarter
Emcure Pharmaceuticals moves up on getting EIR from USFDA for Sanand facility
The USFDA conducted this inspection from May 06, 2026 to May 15, 2026
Emcure Pharmaceuticals gets EIR from USFDA for Sanand facility
The USFDA conducted this inspection from May 06, 2026 to May 15, 2026
Emcure Pharma - Quaterly Results
Emcure Pharma reports Profit after tax of Rs 2001.08 Mln, in the June 2026 quarter
Emcure soars on getting nod to market Poviztra for treatment of non-cirrhotic MASH
The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease
Emcure gets nod to market Poviztra for treatment of non-cirrhotic MASH
The approval enables Emcure to offer the new indication through Poviztra, expanding access to innovator semaglutide for patients living with a progressive liver disease
Emcure Pharmaceuticals rises on inking pact to acquire remaining 12.05% stake in Gennova
The Gennova will become a wholly-owned subsidiary of the company after completion of the transaction
Emcure Pharmaceuticals to acquire remaining 12.05% stake in Gennova
The Gennova will become a wholly-owned subsidiary of the company after completion of the transaction
Emcure Pharmaceuticals informs about acquisition
Emcure Pharmaceuticals informs about investor presentation
Kotak Mahindra Mutual Fund buys stake worth Rs 612 crore in Emcure Pharmaceuticals
Kotak Mahindra Mutual Fund has bought 36 lakh equity shares at price of Rs 1,700 apiece
USFDA concludes cGMP inspection at Emcure Pharmaceuticals’ Gujarat facility
At the conclusion of the inspection, the company was issued a Form 483 with 7 observation(s)
Emcure Pharmaceuticals informs about ESG rating
Emcure Pharma - Quaterly Results
Emcure Pharmaceuticals informs about change in management
Emcure Pharma reports Profit after tax of Rs 2336.97 Mln, in the March 2026 quarter
Emcure Pharmaceuticals reduces Poviztra dose price to expand patient access
The reduced price would be starting at Rs 3,999 per month
Emcure Pharmaceuticals informs about clarification on volume movement letter
Emcure Pharmaceuticals moves up on signing distribution agreement with Roche
Emcure will distribute Roche’s established and globally recognised brands in the nephrology and transplant segment in India
Emcure Pharmaceuticals signs distribution agreement with Roche
Emcure will distribute Roche’s established and globally recognised brands in the nephrology and transplant segment in India
Emcure Pharma - Quaterly Results
Emcure Pharma reports Profit after tax of Rs 2588.51 Mln, in the December 2025 quarter
Emcure Pharmaceuticals inches up on launching semaglutide injection ‘Poviztra’ across India
It comes in a state-of-the-art pen device that provides the convenience of simple administration of precise dosing
Emcure Pharmaceuticals launches semaglutide injection ‘Poviztra’ across India
It comes in a state-of-the-art pen device that provides the convenience of simple administration of precise dosing
Emcure Pharmaceuticals informs about press release
Emcure Pharmaceuticals informs about disclosure
Emcure Pharmaceuticals informs about resignation of company secretary
Emcure Pharmaceuticals informs about investor presentation
Emcure Pharma - Quaterly Results
Emcure Pharma reports Profit after tax of Rs 1176.22 Mln, in the September 2025 quarter
Emcure Pharma, Novo Nordisk India join hands to launch Poviztra in India
As part of the agreement, the company will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra, semaglutide injection 2.4 mg, in India
Emcure Pharmaceuticals surges on acquiring 20.42% stake in Zuventus Healthcare
Zuventus become a wholly owned subsidiary of the company
Emcure Pharmaceuticals acquires 20.42% stake in Zuventus Healthcare
Zuventus become a wholly owned subsidiary of the company
Emcure Pharmaceuticals informs about outcome of board meeting
Emcure Pharma reports Profit after tax of Rs 1227.89 Mln, in the June 2025 quarter
Emcure Pharma - Quaterly Results
Emcure Pharma - Quaterly Results
Emcure Pharma - Quaterly Results
Emcure Pharmaceuticals gains on entering into agreement with Sanofi India
Emcure will exclusively distribute and promote the company’s OAD range of products that include well-established brands like Amaryl and Cetapin
Emcure Pharmaceuticals enters into agreement with Sanofi India
Emcure will exclusively distribute and promote the company’s OAD range of products that include well-established brands like Amaryl and Cetapin
USFDA concludes PAI at Emcure Pharmaceuticals’ Gujarat manufacturing facility
The inspection concluded without issuance of Form 483 (zero observations)
Emcure Pharmaceuticals incorporates wholly owned subsidiary
Earlier, the Board of Directors of the company at its meeting held on June 21, 2025, had approved the same
Emcure Pharmaceuticals informs about incorporation of WOS
Emcure Pharmaceuticals jumps on getting nod for acquiring 20.42% stake of Zuventus Healthcare
The Board of Directors of the company at its meeting held on June 21, 2025, has approved the same
Emcure Pharmaceuticals gets nod to incorporate wholly owned subsidiary
The Board of Directors of the company at its meeting held on June 21, 2025, has approved the same
Emcure Pharmaceuticals informs about updates
Emcure Pharmaceuticals informs about press release
Emcure Pharmaceuticals informs about acquisition
Emcure Pharmaceuticals informs about outcome of board meeting
Emcure Pharmaceuticals gets nod for acquiring 20.42% stake of Zuventus Healthcare
The Board of Directors of the company at its meeting held on June 21, 2025, has approved the same
Emcure Pharmaceuticals inks pact to purchase electricity generated from TUPL
Cost of acquisition is Rs 3.72 crore
Emcure Pharmaceuticals touches the roof on getting nod to incorporate wholly-owned subsidiary
The Board of Directors of the Company in their meeting held May 22, 2025, has approved the same
Emcure Pharmaceuticals gets nod to incorporate wholly-owned subsidiary
The Board of Directors of the Company in their meeting held May 22, 2025, has approved the same
Emcure Pharmaceuticals informs about change in management
Emcure Pharma - Quaterly Results
Emcure Pharma - Quaterly Results
Emcure Pharma reports Profit after tax of Rs 1395.57 Mln, in the March 2025 quarter
Emcure Pharma - Quaterly Results
Emcure Pharmaceuticals gets EIR for Pune manufacturing facility
USFDA has classified the inspection of the said facility as ‘Voluntary Action Indicated’
Emcure Pharmaceuticals’ arm inks pact with Manx Healthcare
Under the APA, Tillomed will acquire Manx’s product portfolio inclusive of relevant Dossiers, Marketing Authorisations, Intellectual Property and the relevant stocks
Emcure Pharmaceuticals’ arm inks in-licensing agreement with WiQo
The collaboration is set to redefine the landscape of non-invasive skin treatments in the region
Emcure Pharmaceuticals gains on expanding OTC Portfolio with Arth Supplements
Emcure has partnered with acclaimed actor and women’s health advocate Vidya Balan
Emcure Pharmaceuticals expands OTC Portfolio with Arth Supplements
Emcure has partnered with acclaimed actor and women’s health advocate Vidya Balan
Emcure Pharma - Quaterly Results
Emcure Pharma - Quaterly Results
Emcure Pharma reports Profit after tax of Rs 502.04 Mln, in the December 2024 quarter
Emcure Pharmaceuticals informs about press release
Emcure Pharmaceuticals inaugurates R&D centre in Gujarat
The new ERC facility is designed to accelerate pharmaceutical innovation with state-of-the-art laboratories and advanced equipment for each of the dosage forms
Emcure Pharmaceuticals informs about compliance certificate
Emcure Pharmaceuticals informs about newspaper publication
Emcure Pharma - Quaterly Results
Emcure Pharma - Quaterly Results
Emcure Pharma reports Profit after tax of Rs 869.21 Mln, in the September 2024 quarter
Emcure Pharma - Quaterly Results
Emcure Pharmaceuticals informs about press release
Emcure Pharmaceuticals signs agreement with Gilead Sciences Ireland UC
This strategic partnership underscores Emcure’s commitment to innovative affordable global healthcare
Emcure Pharmaceuticals informs about closure of trading window
Emcure Pharmaceuticals inches up on getting nod to incorporate wholly-owned subsidiary
A Committee of the Board of Directors of the Company in their meeting held on September 13, 2024, has inter-alia approved the same
Emcure Pharmaceuticals gets nod to incorporate wholly-owned subsidiary
A Committee of the Board of Directors of the Company in their meeting held on September 13, 2024, has inter-alia approved the same